VHT vs XLV

VHTAVanguard Health Care ETF

XLVAState Street Health Care Select Sector SPDR ETF

In short

VHT The whole US health care sector in one ticket: roughly 400 stocks, an index that reaches well past the megacaps, and a nine-basis-point fee. Trading since 2004, it is one of the category's originals.

XLV Live since 1998, XLV is the original way to own health care: about 60 S&P 500 names, a 0.08% fee, and one of the busiest tickers in the sector. Big pharma and device makers, not small-cap biotech.

Stated mandate

VHT The fund seeks to track a benchmark index measuring the investment return of health care stocks.

XLV The fund seeks to track, before expenses, the price and yield performance of the Health Care Select Sector Index, which represents the health care sector of the S&P 500 Index.

Why people hold it

• VHT Costs 0.09% a year while the typical fund in its health care peer group charges 0.50%. Same sector, a fraction of the toll.
• Roughly 400 holdings drawn from an investable-market index, so mid and small health care companies count too, not just the sector's giants.vanguard.com
• Two decades old, now a multi-billion-dollar fund, moderately traded, and it has hugged its benchmark closely. Pays out quarterly.
• On cost, tracking and tradability together, it stands among the strongest builds in a 24-fund health care cohort.

• XLV 0.08% a year against a cohort median of 0.50%. That ties it with FHLC as the cheapest in the group and edges VHT at 0.09%.
• One of the most actively traded funds in its category, which generally keeps bid-ask spreads thin whether you trade 10 shares or 10,000.
• Launched December 1998 as one of the first US sector funds, and it has tracked its S&P 500 health care index closely ever since.
• Covers the whole sector in one line: pharma, devices, providers, biotech, life-science tools and health tech. Pays quarterly.ssga.com

Worth knowing

• VHT FHLC and XLV each shave a basis point off the fee. If the fee line is your only tiebreaker, VHT is not the final word.
• One sector, one news cycle. Drug pricing rules, patent expirations and regulatory decisions can move the entire basket at once.vanguard.com
• Cap-weighted with a 25/50 diversification rule, so no single name can dominate outright, but the largest pharma and insurer positions still steer most of the ride.vanguard.com

• XLV Cap-weighted and about 60 names deep, so the largest drug and device makers carry most of the weight.ssga.com
• S&P 500 members only. Mid- and small-cap health care names sit outside the mandate.
• One sector, one set of headlines: drug pricing rules, patent expirations and policy shifts move the whole basket together.

Full VHT profile⁠

Full XLV profile⁠